Tyligand Bioscience was recognized in the first KPMG China 2021 Biotechnology Innovation 50 Enterprises

KPMG's selection activity covers six major unlisted companies in biopharmaceuticals, cell therapy, gene therapy, companion diagnostics, medical devices, and clinical research, from the perspective of technology and product line leadership, core management team and R&D team background The participating companies will be evaluated on 5 main core dimensions, including capital market activity, product pipeline richness, and financial health. The selection of KPMG China's Biotechnology Innovation 50 Enterprises demonstrates the recognition and encouragement of the industry and professional institutions for Tyrena's innovation capabilities and future development.

Since its establishment in 2018, Tyligand has always focused on patient accessibility and independently innovated for the global market. So far, the company has established a rich product portfolio of preclinical and clinical stage projects through completely independent research and development, as well as the world's first dual-function immune agonist (DATIA®) research and development platform and innovative payload platform of antibody-drug conjugate ADC. Among them, the leading product, TSN084, is a multi-target kinase inhibitor including the innovative target CDK8/19. It has completed the first human trial in March 2022 at the MD Anderson Cancer Center in the United States.

Dr. Tony Zhang, co-founder and CEO of Tyligand, said:

"Thanks to KPMG China for the nomination and the recognition of investors, as well as the support of many partners. Tyligand is based on the design and synthesis capabilities of complex small molecules, combined with cutting-edge biological progress and technical advantages such as AI, focusing on non-significant connections in cross-fields , to improve the quality, speed, and success rate of R&D innovation. The dual-function immune agonist (DATIA®), pioneered by Tyligand’s team, first induces tumor cells to produce immune factors, and then induces their apoptosis to help the establishment of the adaptive immune system And achieve the ultimate goal of eradicating tumors. This will provide a different way of thinking and approach to conquer cancer. We will use the DATIA® platform to strengthen external cooperation, expand the speed and dimension of its application, and develop more clinically proven molecular."